The theory is straightforward: slower absorption means a gentler onset of the medication effects, reducing the sharp spike that can trigger bloating and nausea in sensitive individuals
[DOI] [PubMed] [Google Scholar] 54.Tay J.Q
"You need an exam," he said
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
While superior to placebo, this falls slightly below the commonly cited 5 % threshold considered clinically meaningful for individuals with a BMI below 35 kg/m, and well below the larger reductions often recommended for those with severe obesity
Significant Limitations : High costs, access barriers, tolerability issues, and sustainability concerns prevent these agents from achieving their full transformative potential at a population level